Canbridge Pharmaceuticals
Canbridge Pharmaceuticals, a leading biopharmaceutical company headquartered in China (CN), is dedicated to the development and commercialisation of innovative therapies for patients with unmet medical needs. Founded in 2010, the company has established a strong presence in the oncology and rare disease sectors, focusing on advanced biologics and small molecule drugs. With a robust pipeline of products, Canbridge Pharmaceuticals stands out for its commitment to precision medicine and strategic partnerships that enhance its research capabilities. The company has achieved significant milestones, including successful clinical trials and collaborations with global pharmaceutical leaders, solidifying its position in the competitive biopharmaceutical landscape. Through its unique approach to drug development, Canbridge continues to make strides in improving patient outcomes and addressing critical health challenges.
DitchCarbon Score
How does Canbridge Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Canbridge Pharmaceuticals's score of 13 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Canbridge Pharmaceuticals's reported carbon emissions
In 2023, Canbridge Pharmaceuticals reported total carbon emissions of approximately 261,843 kg CO2e, comprising 9,777 kg CO2e from Scope 1, 254,657 kg CO2e from Scope 2, and 1,409 kg CO2e from Scope 3. This marked a significant reduction in emissions compared to 2022, where total emissions were about 724,145 kg CO2e, with Scope 1 emissions at 5,390 kg CO2e, Scope 2 at 715,268 kg CO2e, and Scope 3 at 2,477 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, achieving a notable decrease in Scope 2 emissions from 2022 to 2023. However, there are currently no specific reduction targets or climate pledges disclosed by Canbridge Pharmaceuticals. The company continues to monitor and report its emissions across all scopes, reflecting an ongoing commitment to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 23,288 | 0,000 | 0,000 |
| Scope 2 | 117,459 | 000,000 | 000,000 |
| Scope 3 | 890 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Canbridge Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
